New Monoclonal Antibody E29 for Epithelial Membrane Antigen
Author Information
Author(s): E. Heyderman, I. Strudley, G. Powell, T.C. Richardson, J. L. Cordell, D.Y. Mason
Primary Institution: UMDS St Thomas Hospital and Nuffield Department of Pathology, John Radcliffe Hospital
Hypothesis
The study aims to compare the immunocytochemical reactivity of a new monoclonal antibody E29 with existing polyclonal and monoclonal antibodies against epithelial membrane antigen (EMA).
Conclusion
The monoclonal antibody E29 provides clearer results and better discrimination between cells and stroma compared to HMFG-2, making it suitable for routine diagnostic histopathology.
Supporting Evidence
- E29 showed a cleaner result than HMFG-2, allowing for better differentiation between cells and stroma.
- Polyclonal antibodies produced stronger staining in colorectal carcinomas and lactating breast compared to monoclonal antibodies.
- All sections showed positive staining with all antibodies, indicating their effectiveness in detecting EMA.
Takeaway
Scientists created a new antibody called E29 to help doctors see cancer cells better under a microscope, and it works really well.
Methodology
The study used an indirect immunoperoxidase technique to compare the staining of various tissues with different antibodies.
Potential Biases
Potential cross-reactivity of monoclonal antibodies may affect discrimination between tissues.
Limitations
The study did not establish the specificity of the antibodies used, focusing instead on their distribution of staining.
Participant Demographics
The study examined 25 tissue samples, including 17 malignant and 8 benign tissues.
Want to read the original?
Access the complete publication on the publisher's website